The Claim

In clinical programs such as IMPROVE-IT, FOURIER, PROFICIO, and ODYSSEY, patients receiving lipid-lowering therapies that achieve very low LDL cholesterol levels do not show a higher prevalence of adverse effects compared to patients with higher LDL-C levels.

Source: Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis.

What the research says

Roughly balanced

Support and challenge are close. The picture may shift as more studies come in.

Supports
1score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

People who take cholesterol-lowering drugs and get their bad cholesterol really low don’t seem to have more side effects than those who don’t get it as low.

See the scientific wording

Patients treated with lipid-lowering therapies that achieve extremely low LDL cholesterol levels in clinical programs such as IMPROVE-IT, FOURIER, PROFICIO, and ODYSSEY do not exhibit increased prevalence of adverse effects compared to those with higher LDL-C levels.

What the research says

1 study

  1. Study: Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis.

    The study looks at people who took cholesterol-lowering drugs and had very low LDL levels, just like in the claim, and found they didn’t have more side effects.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.